Intent Solutions announced a partnership with the University of Kentucky in a $15 million federal grant program aimed at eliminating hepatitis C in an eastern Kentucky county that has particularly high rates of chronic infection, according to a press release.
The Kentucky Viral Hepatitis Treatment Study, known as KeY Treat, is part of the contract between the company and university because the study’s design is intended to manage the dispensation of HCV medications to 900 individuals in the program. Gilead Sciences donated the medications to be used with a value of approximately $20

Source link